UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of July 2018
Commission File Number: 001-32001
Aptose Biosciences Inc.
(Translation of registrant's name into English)
251 Consumers Road, Suite 1105 Toronto, Ontario M2J 4R3 Canada
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F [ ] Form 40-F [ X ]
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):
On July 9, 2018, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
(c) Exhibit 99.1. Press release dated July 9, 2018
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Aptose Biosciences Inc. | ||
(Registrant) | ||
Date: July 9, 2018 | /s/ Gregory K. Chow | |
Gregory K. Chow | ||
Senior Vice President and Chief Financial Officer | ||
EXHIBIT 99.1
Aptose Biosciences to Participate at the Oppenheimer & Co. Inc. Boston Oncology Insight Summit and 1x1 Day
SAN DIEGO and TORONTO, July 09, 2018 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ:APTO) (TSX:APS) today announced that William G. Rice, Ph.D., Chairman, President and Chief Executive Officer and Gregory Chow, Senior Vice President and Chief Financial Officer, will participate at the upcoming Oppenheimer & Co. Inc. Boston Oncology Insight Summit to be held at the Whitehead Institute on July 10, 2018 and 1x1 Day to be held at the Four Seasons Hotel on July 11, 2018 in Boston, MA.
About Aptose Biosciences Inc.
Aptose Biosciences is a clinical-stage biotechnology company committed to developing personalized therapies addressing unmet medical needs in oncology, with an initial focus on hematology. The company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities. APTO-253, the only clinical stage inhibitor of MYC oncogene expression, is in a Phase 1b clinical trial for the treatment of patients with relapsed or refractory acute myeloid leukemia (AML) or high risk MDS. CG-806 is an oral, first-in-class pan-FLT3/pan-BTK multi-cluster kinase inhibitor expected to reach IND submission by the end of 2018 and is planned for development to treat AML and certain B cell malignancies. For further information, please visit www.aptose.com.
For further information, please contact: | |
Aptose Biosciences Inc. | |
Greg Chow | |
Senior Vice President, Chief Financial Officer | |
650-718-5028 | |
gchow@aptose.com | |
SMP Communications | LifeSci Advisors |
Susan Pietropaolo | Michael Wood, Managing Director |
201-923-2049 | 646-597-6983 |
susan@smpcommunications.com | mwood@lifesciadvisors.com |